Investigation and pending class action lawsuit against Pfizer on behalf of a proposed class of direct purchasers of the brand-name prescription drug Neurontin.
The class action lawsuit alleges that Pfizer, Inc., one of the nation's largest pharmaceutical manufacturers, and its subsidiary Warner-Lambert Co., illegally maintained a monopoly in the market for Neurontin, a popular anti-epilepsy drug, by filing sham patent litigation against generic competitors in order to delay the marketing of less expensive generic substitutes for Neurontin.
The lawsuit alleges that, as a result, all purchasers paid artificially inflated prices for the Neurontin drug entity. The class action lawsuit would include all entities that purchased Neurontin directly from Pfizer between January 16, 2000 and the present.
Do not change medications without first consulting your doctor.
The information provided on ClassAdvocate.com is general in nature,
does not apply to any particular factual situation, and is not and
should not be taken as legal or other professional advice. We make no
commitment or warranty that the factual, legal or any other information
on ClassAdvocate.com, or on any linked website, is accurate, complete,
error-free, or current. As such, you should not rely on such information,
and should seek professional advice if and as you determine appropriate.
ClassAdvocate.com is not a lawyer referral service, and no attorney-client
or confidential relationship is or should be formed by use of the site.
The investigations listed on ClassAdvocate.com are attorney advertisements
and do not in any way constitute a referral or endorsement by ClassAdvocate.com
or any approved or authorized lawyer referral service.